Progenesis Technologies, LLC
Bioengineered alginate biopolymers with customizable monomer composition and properties produced from engineered P. aeruginosa bacteria
- Sector
- Medtech
- Headquarters
- SOUTH CHARLESTON, WV
- Founded
- 2006
- Latest Form D
- $100K, Jul 2010
- Total capital
- $2M
- Federal grants
- $1.9M
- 3 awards · 2015–2018
- Rank in peer group#2 of 27
- Private capital raised
- $100K
- 1 Form D · last Jul 2010
- 195 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Bioengineering a non-pathogenic bacteria to produce medically-relevant biopolymers$650K
- Federal grantHealth and Human S · Phase II · Bioengineering a non-pathogenic bacteria to produce medically-relevant biopolymers$1.1M
- Federal grantHealth and Human S · Phase I · Bioengineering a non-pathogenic bacteria to produce medically-relevant biopolymers$144K
- Private capital raisedForm D · SEC · 1st filing$100K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 27 peers
Line = medianMedtech · Material
- Federal grants#2 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard M NilesResearcherExecutive OfficerLinked by $1.7M in grants as PI
- Deepay M MukerjeeExecutive OfficerNamed in SEC Form D filings
- Hongwei M YuExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingCulture Medium and Methods for Producing Alginate From Stable Mucoid Strains of Pseudomonas AeruginosaUSPTOApplication 14515558
Related companies, and why
- PetVivo Holdings, Inc.Similar federal contract value in Medtech · null in contracts
- Gravidi, Inc.Similar federal contract value in Medtech · null in contracts
- Enamel Pure Inc.Similar federal contract value in Medtech · null in contracts
- OPTICYTE INCSimilar federal contract value in Medtech · null in contracts
- Sonablate Corp.Similar federal contract value in Medtech · null in contracts
- ENDOLYNX INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .